The evidence for a beneficial role of vitamin A in multiple sclerosis

CNS Drugs

Volumn 28, Issue 4, 2014, Pages 291-299

  Fragoso, Yara Dadalti ^a   Stoney, Patrick N ^a   McCaffery, Peter J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOL; VITAMIN D;

ADD ON THERAPY; ARTICLE; B LYMPHOCYTE; BRAIN; CENTRAL NERVOUS SYSTEM; COGNITION; DENDRITIC CELL; DEPRESSION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HELMINTHIASIS; HELPER CELL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LYMPHOCYTE CULTURE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL; VITAMIN SUPPLEMENTATION; ANIMAL; BLOOD; DIET SUPPLEMENTATION;

ANIMALS; DIETARY SUPPLEMENTS; HUMANS; MULTIPLE SCLEROSIS; TRETINOIN; VITAMIN A;

EID: 84899082176     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0148-4     Document Type: Article

References (98)

1. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008;8:685-8.
2. Farso MC, Krantic S, Rubio M, Safati M, Quirion R. The retinoid, 6-[3-ada-mantyl-4-hydroxyphenyl]-2-napthalene carboxylic acid, controls proliferative, morphological, and inflammatory responses involved in microglial activation without cytotoxic effects. Neuroscience. 2011;192:172-84.
3. Kim CH. Retinoic acid, immunity, and inflammation. Vitam Horm. 2011;86:83-101.
4. Ross AC. Vitamin A and retinoic acid in T cell-related immunity. Am J Clin Nutr. 2012;96:1166S-72S.
5. May J, McCaffery PJ. Retinoic acid signaling in the nervous system of adult vertebrates. Neuroscientist. 2004;10:409-21.
6. Shearer KD, Stoney PN, Morgan PJ, McCaffery PJ. A vitamin for the brain. Trends Neurosci. 2012;35:733-41.
7. Filippi M, Preziosa P, Rocca MA. Vitamin A: yet another player in multiple sclerosis pathogenesis? Expert Rev Clin Immunol. 2013;9:113-5.
8. O'Byrne SM, Blaner WS. Retinol and retinyl esters: biochemistry and physiology. J Lipid Res. 2013;54:1731-43.
9. Vieira AV, Schneider WJ, Vieira PM. Retinoids: transport, metabolism, and mechanisms of action. J Endocrinol. 1995;146:201-7.
10. Nagpal S, Chandraratna RA. Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000;6:919-31.
11. Wolf G. Is 9-cis-retinoic acid the endogenous ligand for the retinoic acid-X receptor? Nutr Rev. 2006;64:532-8.
12. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene. 2004;328:1-16.
13. Hua S, Kittler R, White KP. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 2009;137:1259-71.
14. Adan RA, Cox JJ, Beischlag TV, Burbach JP. A composite hormone response element mediates the transactivation of the rat oxytocin gene by different classes of nuclear hormone receptors. Mol Endocrinol. 1993;7:47-57.
15. Ransom J, Morgan PJ, McCaffery PJ. Stoney PN. The rhythm of retinoids in the brain. J Neurochem. 2013 (in press).
16. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol. 2012;142:2-8.
17. Nakayamada S, Takahashi H, Kanno Y, O'Shea JJ. Helper T cell diversity and plasticity. Curr Opin Immunol. 2012;24:297-302.
18. Nowak EC, Noelle RJ. Interleukin-9 as a T helper type 17 cytokine. Immunology. 2010;131:169-73.
19. Hall JA, Grainger JR, Spencer SP, Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunity. 2011;35:13-22.
20. Sidell N, Schlichter L. Retinoic acid blocks potassium channels in human lymphocytes. Biochem Biophys Res Commun. 1986;138:560-7.
21. Bosma M, Sidell N. Retinoic acid inhibits Ca2+ currents and cell proliferation in a B-lymphocyte cell line. J Cell Physiol. 1988;135:317-23.
22. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-8.
23. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448:484-7.
24. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
25. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317:256-60.
26. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441:231-4.
27. Di Caro V, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N. Retinoic acid-producing, ex vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B-lymphocytes. Clin Exp Immunol. 2013;174:302-17.
28. Ziegler SF, Buckner JH. FOXP3 and the regulation of Treg/Th17 differentiation. Microbes Infect. 2009;11:594-8.
29. Zúñiga LA, Jain R, Haines C, Cua DJ. Th17 cell development: from the cradle to the grave. Immunol Rev. 2013;252:78-88.
30. Wan YY, Flavell RA. Yin-Yang functions of TGF-β and Tregs in immune regulation. Immunol Rev. 2007;220:199-213.
31. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med. 2007;204:1765-74.
32. Mauri C, Blair PA. Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol. 2010;6:636-43.
33. DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann NY Acad Sci. 2010;1183:38-57.
34. Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, et al. Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. J Exp Med. 2013;210:1961-76.
35. Zhu B, Buttrick T, Bassil R, Zhu C, Olah M, Wu C, et al. IL-4 and retinoic acid synergistically induce regulatory dendritic cells expressing Aldh1a2. J Immunol. 2013;161:139-51.
36. Maden M. Retinoid signalling in the development of the central nervous system. Nat Rev Neurosci. 2002;3:843-53.
37. Fragoso YD, Shearer KD, Sementilli A, de Carvalho LV, McCaffery PJ. High expression of retinoic acid receptors and synthetic enzymes in the human hippocampus. Brain Struct Funct. 2012;217:473-83.
38. Soden ME, Chen L. Fragile X protein FMRP is required for homeostatic plasticity and regulation of synaptic strength by retinoic acid. J Neurosci. 2010;30:16910-21.
39. Carmona-Mora P, Walz K. Retinoic Acid Induced 1, RAI1: A dosage sensitive gene related to neurobehavioral alterations including autistic behavior. Curr Genomics. 2010;11:607-17.
40. Wan C, Yang Y, Li H, La Y, Zhu H, Jiang L, Chen Y, Feng G, He L. Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients. J Proteome Res. 2006;5:3213-6.
41. Jacobs S, Lie DC, DeCicco KL, Shi Y, DeLuca LM, Gage FH, et al. Retinoic acid is required early during adult neurogenesis in the dentate gyrus. Proc Natl Acad Sci USA. 2006;103:3902-7.
42. Goodman T, Crandall JE, Nanescu SE, Quadro L, Shearer K, Ross A, et al. Patterning of retinoic acid signaling and cell proliferation in the hippocampus. Hippocampus. 2012;22:2171-83.
43. Shearer KD, Goodman TH, Ross AW, Reilly L, Morgan PJ, McCaffery PJ. Photoperiodic regulation of retinoic acid signaling in the hypothalamus. J Neurochem. 2010;112:246-57.
44. Chiang MY, Misner D, Kempermann G, Schikorski T, Giguère V, Sucov HM, et al. An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression. Neuron. 1998;21:1353-61.
45. Nomoto M, Takeda Y, Uchida S, Mitsuda K, Enomoto H, Saito K, et al. Dysfunction of the RAR/RXR signaling pathway in the forebrain impairs hippocampal memory and synaptic plasticity. Mol Brain. 2012;5:8.
46. Etchamendy N, Enderlin V, Marighetto A, Pallet V, Higueret P, Jaffard R. Vitamin A deficiency and relational memory deficit in adult mice: relationships with changes in brain retinoid signalling. Behav Brain Res. 2003;145:37-49.
47. Mingaud F, Mormede C, Etchamendy N, Mons N, Niedergang B, Wietrzych M, et al. Retinoid hyposignaling contributes to aging-related decline in hippocampal function in short-term/working memory organization and long-term declarative memory encoding in mice. J Neurosci. 2008;28:279-91.
48. Chen N, Napoli JL. All-trans-retinoic acid stimulates translation and induces spine formation in hippocampal neurons through a membrane-associated RARalpha. FASEB J. 2008;22:236-45.
49. Chen N, Onisko B, Napoli JL. The nuclear transcription factor RARalpha associates with neuronal RNA granules and suppresses translation. J Biol Chem. 2008;283:20841-7.
50. Anzano MA, Lamb AJ, Olson JA. Growth, appetite, sequence of pathological signs and survival following the induction of rapid, synchronous vitamin A deficiency in the rat. J Nutr. 1979;109:1419-31.
51. Bitarafan S, Harirchian MH, Sahraian MA, Keramatipour M, Beladi Moghadam N, Togha M, et al. Impact of vitamin A supplementation on RAR gene expression in multiple sclerosis patients. J Mol Neurosci. 2013;51:478-84.
52. Mohammadzadeh Honarvar N, Harirchian MH, Koohdani F, Siassi F, Abdolahi M, Bitarafan S, et al. The effect of vitamin A supplementation on retinoic acid-related orphan receptor γt (RORγt) and interleukin-17 (IL-17) gene expression in Avonex-treated multiple sclerotic patients. J Mol Neurosci. 2013;51:749-53.
53. Bright JJ, Walline CC, Kanakasabai S, Chakraborty S. Targeting PPAR as a therapy to treat multiple sclerosis. Expert Opin Ther Targets. 2008;12(12):1565-75.
54. Xu J, Chavis JA, Racke MK, Drew PD. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol. 2006;176:95-105.
55. Zhang-Gandhi JCX, Drew PD. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J Neuroimmunol. 2007;183:50-9.
56. Huang JK, Jarjour AA, Nait Oumesmar B, Kerninon C, Williams A, Krezel W, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci. 2011;14:45-53.
57. Huang JK, Franklin RJ. Regenerative medicine in multiple sclerosis: identifying pharmacological targets of adult neural stem cell differentiation. Neurochem Int. 2011;59(3):329-332.x.
58. Massacesi L, Abbamondi AL, Giorgi C, Sarlo F, Lolli F, Amaducci L. Suppression of experimental allergic encephalomyelitis by retinoic acid. J Neurol Sci. 1987;80:55-64.
59. Massacesi L, Abbamondi AL, Sarlo F, Amaducci L. The control of experimental allergic encephalomyelitis with retinoic acid. Further studies. Riv Neurol. 1987;57:166-9.
60. Massacesi L, Castigli E, Vergelli M, Olivotto J, Abbamondi AL, Sarlo F, et al. Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats. J Clin Invest. 1991;88:1331-7.
61. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol. 1995;154:450-8.
62. Vergelli M, Olivotto J, Castigli E, Gran B, Raimondi L, Pirisino R, et al. Immunosuppressive activity of 13-cis-retinoic acid in rats: aspects of pharmacokinetics and pharmacodynamics. Immunopharmacology. 1997;37:191-7.
63. Xu J, Drew PD. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol. 2006;171:135-44.
64. Xu J, Storer PD, Chavis JA, Racke MK, Drew PD. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res. 2005;81:403-11.
65. Petkovich PM, Heersche JN, Tinker DO, Jones G. Retinoic acid stimulates 1,25-dihydroxyvitamin D3 binding in rat osteosarcoma cells. J Biol Chem. 1984;259:8274-80.
66. Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, Kakeda M, Kurokawa I, Mizutani H, Kupper TS. Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression. J Allergy Clin Immunol. 2008;121:148-57.
67. Székely JI, Pataki Á. Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: a short review. Expert Rev Respir Med. 2012;6:683-704.
68. Ikeda U, Wakita D, Ohkuri T, Chamoto K, Kitamura H, Iwakura Y, Nishimura T. 1α,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunol Lett. 2010;134:7-16.
69. Ross AC, Chen Q, Ma Y. Vitamin A and retinoic acid in the regulation of B-cell development and antibody production. Vitam Horm. 2011;86:103-26.
70. Warren TR. The increased prevalence of multiple sclerosis among people who were born and bred in areas where goitre is endemic. Med Hypotheses. 1984;14:111-4.
71. Campbell AMG, Crow RS, Lang DW. Goitre and disseminated sclerosis. Br Med J. 1960;1:200-1.
72. Torkildsen Ø, Løken-Amsrud KI, Wergeland S, Myhr KM, Holmøy T. Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurol Scand Suppl. 2013;196:16-23.
73. Zhang QY, Huang JH, Li HZ, Guo HT, Zhong YQ, Wang YM, Pei JM. Myelin-basic protein-reactive specific CD4+ and CD8+ NK lymphocytes induce morphological changes in neuronal cell bodies and myelin sheaths: implications for multiple sclerosis. Arch Med Res. 2008;39:45-51.
74. Lovett-Racke AE, Racke MK. Retinoic acid promotes the development of Th2-like human myelin basic protein-reactive T cells. Cell Immunol. 2002;215:54-60.
75. Zhang SM, Hernán MA, Olek MJ, Spiegelman D, Willett WC, Ascherio A. Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology. 2001;57:75-80.
76. Kalz F, Schafer A. Vitamin A serum levels after ingestion of different vitamin A preparations. Can Med Assoc J. 1958;79:918-9.
77. Besler HT, Comoǧlu S, Okçu Z. Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr Neurosci. 2002;5:215-20.
78. Royal W 3rd, Gartner S, Gajewski CD. Retinol measurements and retinoid receptor gene expression in patients with multiple sclerosis. Mult Scler. 2002;8:452-8.
79. Løken-Amsrud KI, Myhr KM, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, et al. Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Mult Scler. 2013;19:451-7.
80. Løken-Amsrud KI, Myhr KM, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, et al. Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. PLoS ONE. 2013;8:e54417.
81. Runia TF, Hop WCJ, de Rijke YB, Hintzen RQ. Vitamin A is not associated with exacerbations in multiple sclerosis. Mult Scler Relat Disord. 2014;3:34-9.
82. Qu ZX, Pliskin N, Jensen MW, White D, Arnason BG. Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis. Arch Neurol. 2001;58:87-90.
83. McQualter JL, Bernard CC. Multiple sclerosis: a battle between destruction and repair. J Neurochem. 2007;100:295-306.
84. Jafarirad S, Siassi F, Harirchian MH, Amani R, Bitarafan S, Saboor-Yaraghi A. The effect of vitamin A supplementation on biochemical parameters in multiple sclerosis patients. Iran Red Crescent Med J. 2013;15:194-8.
85. Jafarirad S, Siassi F, Harirchian MH, Sahraian MA, Eshraghian MR, Shokri F, et al. The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. J Neurosci Rural Pract. 2012;3:294-8.
86. Sundgren M, Maurex L, Wahlin Å, Piehl F, Brismar T. Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis. Arch Clin Neuropsychol. 2013;28:144-55.
87. Luo T, Wagner E, Dräger UC. Integrating retinoic acid signaling with brain function. Dev Psychol. 2009;45:139-50.
88. Ormerod AD, Thind CK, Rice SA, Reid IC, Williams JH, McCaffery PJ. Influence of isotretinoin on hippocampal-based learning in human subjects. Psychopharmacology (Berl). 2012;221:667-74.
89. Jimenez-Jimenez FJ, Molina JA, de Bustos F, Ortí-Pareja M, Benito-León J, Tallón-Barranco A, Gasalla T, Porta J, Arenas J. Serum levels of β-carotene, α-carotene and vitamin A in patients with Alzheimer's disease. Eur J Neurol. 1999;6:495-7.
90. Obulesu M, Dowlathabad MR, Bramhachari PV. Carotenoids and Alzheimer's disease: an insight into therapeutic role of retinoids in animal models. Neurochem Int. 2011;59:535-41.
91. Feinstein A. Multiple sclerosis and depression. Mult Scler. 2011;17:1276-81.
92. Klevan G, Jacobsen CO, Aarseth JH, Myhr KM, Nyland H, Glad S, Lode K, Figved N, Larsen JP, Farbu E. Health related quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurol Scand. 2014;129(1):21-6.
93. Hashmi AM, Butt Z, Umair M. Is depression an inflammatory condition? A review of available evidence. J Pak Med Assoc. 2013;63:899-906.
94. Madeeh Hashmi A, Awais Aftab M, Mazhar N, Umair M, Butt Z. The fiery landscape of depression: a review of the inflammatory hypothesis. Pak J Med Sci. 2013;29(3):877-84.
95. Correale J, Farez MF. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol. 2011;233:6-11.
96. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol. 2007;61:97-108.
97. Correale J, Farez MF. Parasite infections in multiple sclerosis modulate immune responses through a retinoic acid-dependent pathway. J Immunol. 2013;191(7):3827-37.
98. Maizels RM, Balic A, Gomez-Escobar N, Nair M, Taylor MD, Allen JE. Helminth parasites: masters of regulation. Immunol Rev. 2004;201:89-116.